Impact of molecular profile on switch maintenance to paclitaxel plus ramucirumab (PTX-RAM) versus continuation of first-line fluoropyrimidine and oxaliplatin (FOX) chemotherapy (ChT) in patients (pts) with advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: An exploratory endpoint of the ARMANI phase 3 randomized trial.
Year: 2026
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Paolo Manca, Margherita Ambrosini, Alessandra Raimondi, Michele Prisciandaro, Floriana Nappo, Stefano Tamberi, Lorenzo Fornaro, Elisa Giommoni, Andrea Spallanzani, Samantha Di Donato, Ferdinando De Vita, Alessandro Bittoni, Antonia Strippoli, Giovanni Pennoni, Smruthy Sivakumar, Alexa Betzig Schrock, Sabina Murgioni, Sara Lonardi, Filippo Pietrantonio, Giovanni Randon
Institutions: Fondazione IRCCS Istituto Nazionale dei Tumori, Istituto Oncologico Veneto, Ospedale "Santa Maria delle Croci" di Ravenna, Azienda Ospedaliera Universitaria Pisana, Azienda Ospedaliero-Universitaria Careggi, University of Modena and Reggio Emilia, Azienda Ospedaliero-Universitaria di Modena, Ospedale di Prato Santo Stefano, University of Campania "Luigi Vanvitelli", Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Agostino Gemelli University Polyclinic, Foundation Medicine (United States)
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7162499345
Cites:
Cited by:
Related to: